Sudeep Pharma Q1 FY27 Concall Transcript: Revenue Up 27%, EBITDA Margin 34.7%
SUDEEPPHRM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sudeep Pharma filed Q1 FY27 earnings call transcript. Revenue grew 27% YoY to INR158.3 crore, EBITDA up 25% to INR54.9 crore with 34.7% margin, PAT up to INR40.6 crore. Pharma, food and nutrition grew 31% YoY, specialty ingredients up 19%. Management targets EBITDA margins of 37-38%. Bisglycinate Q1 sales already surpassed full FY26. LPG shortage and weak European subsidiary NSS dragged specialty margins to 26%. Greenfield facility FDA approval expected this quarter, supplies from Q3. Battery materials project on track for April 2027 commissioning, evaluating scale-up from 100 KTPA to 200 KTPA by CY30-31, with 8 customer approvals and two more South Korean MOUs signed.
Strong Q1 with 27% revenue growth and resilient margins. Battery materials expansion and bisglycinate traction position the company for sustained multi-year growth.